The Danish National Board of Health has received a number of comments from stakeholders about the Reimbursement Committee's discussion of the reimbursement status of antidiabetic medicines (ATC group A10).
These comments were presented to the Reimbursement Committee at its meeting held on 28 February 2012. The comments are available in Danish in the box to the right.
The Committee will now prepare its recommendation regarding the medicines' reimbursement status.
Please also see our announcement of 13 January 2012 on the comments to be submitted for discussion by the Reimbursement Committee in the right-hand box.